Characterization, in Vivo Evaluation, and Molecular Modeling of Different Propofol-Cyclodextrin Complexes To Assess Their Drug Delivery Potential at the Blood-Brain Barrier Level

In this study, we investigated the ability of the general anesthetic propofol (PR) to form inclusion complexes with modified β-cyclodextrins, including sulfobutylether-β-cyclodextrin (SBEβCD) and hydroxypropyl-β-cyclodextrin (HPβCD). The PR/SBEβCD and PR/HPβCD complexes were prepared and characterized, and the blood-brain barrier (BBB) permeation potential of the formulated PR was examined in vivo for the purpose of controlled drug delivery. The PR/SBEβCD complex was found to be more stable in solution with a minimal degradation constant of 0.25 h-1, a t1/2 of 2.82 h, and a Kc of 5.19 × 103 M-1 and revealed higher BBB permeability rates compared with the reference substance (PR-LIPURO) considering the calculated brain-to-blood concentration ratio (logBB) values. Additionally, the diminished PR binding affinity to SBEβCD was confirmed in molecular dynamics simulations by a maximal Gibbs free energy of binding (ΔGbind = -18.44 kcal·mol-1), indicating the more rapid PR/SBEβCD dissociation. Overall, the results demonstrated that SBEβCD has the potential to be used as a prospective candidate for drug delivery vector development to improve the pharmacokinetic and pharmacodynamic properties of general anesthetic agents at the BBB level.

[1]  V. Stella,et al.  Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. , 1996, Journal of pharmaceutical sciences.

[2]  Tamás Sohajda,et al.  Ionization States, Cellular Toxicity and Molecular Modeling Studies of Midazolam Complexed with Trimethyl-β-Cyclodextrin , 2014, Molecules.

[3]  N. Bodor,et al.  Improved delivery through biological membranes. XXXL: Solubilization and stabilization of an estradiol chemical delivery system by modified beta-cyclodextrins. , 1988, Journal of pharmaceutical sciences.

[4]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[5]  E. Coutinho,et al.  Sulfobutyl Ether7 β-Cyclodextrin (SBE7 β-CD) Carbamazepine Complex: Preparation, Characterization, Molecular Modeling, and Evaluation of In Vivo Anti-epileptic Activity , 2011, AAPS PharmSciTech.

[6]  A. Seelig,et al.  Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion , 1998, The Journal of Membrane Biology.

[7]  N. Roewer,et al.  Sevoflurane-Sulfobutylether-β-Cyclodextrin Complex: Preparation, Characterization, Cellular Toxicity, Molecular Modeling and Blood-Brain Barrier Transport Studies , 2015, Molecules.

[8]  Holger Gohlke,et al.  Converging free energy estimates: MM‐PB(GB)SA studies on the protein–protein complex Ras–Raf , 2004, J. Comput. Chem..

[9]  G. Trapani,et al.  Inclusion Complexation of Propofol with 2-Hydroxypropyl-β- cyclodextrin. Physicochemical, Nuclear Magnetic Resonance Spectroscopic Studies, and Anesthetic Properties in Rat , 1998 .

[10]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[11]  David Baker,et al.  Macromolecular modeling with rosetta. , 2008, Annual review of biochemistry.

[12]  David Calkins,et al.  Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution , 2010, J. Comput. Aided Mol. Des..

[13]  K. Uekama,et al.  Cyclodextrins in drug carrier systems. , 1987, Critical reviews in therapeutic drug carrier systems.

[14]  P A Kollman,et al.  Molecular recognition by beta-cyclodextrin derivatives: FEP vs MM/PBSA study. , 2001, Combinatorial chemistry & high throughput screening.

[15]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[16]  J. Szejtli.  Helical and Cyclic Structures in Starch Chemistry , 1991 .

[17]  T. Egan,et al.  Propofol in a Modified Cyclodextrin Formulation: First Human Study of Dose–Response with Emphasis on Injection Pain , 2011, Anesthesia and analgesia.

[18]  J. Pople,et al.  Self‐Consistent Molecular‐Orbital Methods. IX. An Extended Gaussian‐Type Basis for Molecular‐Orbital Studies of Organic Molecules , 1971 .

[19]  B. Mikami,et al.  Crystal Structure of Recombinant Soybean β-Amylase Complexed with β-Cyclodextrin* , 1998, The Journal of Biological Chemistry.

[20]  B. Damle,et al.  Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). , 2010, Journal of pharmaceutical sciences.

[21]  C. Goodchild,et al.  Alphaxalone Reformulated: A Water-Soluble Intravenous Anesthetic Preparation in Sulfobutyl-Ether-&bgr;-Cyclodextrin , 2015, Anesthesia and analgesia.

[22]  R. Farinotti,et al.  Pharmacokinetics and Protein Binding of Propofol in Patients with Cirrhosis , 1988, Anesthesiology.

[23]  A. Juluri,et al.  Transdermal iontophoretic delivery of a liquid lipophilic drug by complexation with an anionic cyclodextrin. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[24]  P. Kollman,et al.  Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .

[25]  L. Fenart,et al.  Methylated β-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood–brain barrier , 2006 .

[26]  Ajay,et al.  Designing libraries with CNS activity. , 1999, Journal of medicinal chemistry.

[27]  H. Shang,et al.  Formulation, optimization, and pharmacodynamic evaluation of chitosan/phospholipid/β-cyclodextrin microspheres , 2016, Drug design, development and therapy.

[28]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[29]  S. Kampe,et al.  Pharmacological characteristics and side effects of a new galenic formulation of propofol without soyabean oil * , 2003, Anaesthesia.

[30]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[31]  Talmage D Egan,et al.  The Pharmacokinetics and Pharmacodynamics of Propofol in a Modified Cyclodextrin Formulation (Captisol®) Versus Propofol in a Lipid Formulation (Diprivan®): An Electroencephalographic and Hemodynamic Study in a Porcine Model , 2003, Anesthesia and analgesia.

[32]  T. Duke,et al.  A new intravenous anesthetic agent: propofol. , 1995, The Canadian veterinary journal = La revue veterinaire canadienne.

[33]  P. Sebel,et al.  Propofol: A New Intravenous Anesthetic , 1989, Anesthesiology.

[34]  K. Ashok,et al.  Cyclodextrins as Drug Carrier Molecule: A Review , 2008 .

[35]  M. Másson,et al.  Cyclodextrins in topical drug formulations: theory and practice. , 2001, International journal of pharmaceutics.

[36]  M. Brewster,et al.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. , 1996, Journal of pharmaceutical sciences.

[37]  Yun Tang,et al.  In SilicoPrediction of Blood–Brain Partitioning Using a Chemometric Method Called Genetic Algorithm Based Variable Selection , 2008 .

[38]  Anton J. Hopfinger,et al.  Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships , 1994, J. Chem. Inf. Comput. Sci..